標(biāo)題： 1、Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1. The ICAI Study Group. Ischemia Cronica degli Arti Inferiori. 2、Removal ofcysteinylation from an unpaired sulfhydryl in the variable regionof a recombinant monoclonal IgG1 antibody improves homogeneity，stability，and biological activity 3、Pharmacokinetics of fixed-dose combination of tenofovir disoproxil fumarate, lamivudine, and efavirenz: results of a randomized, crossover, bioequivalence study。 4、Synthesis and biological evaluation of bis(methoxymethyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolines as EGFR tyrosine kinase inhibitors. Lee, Yong Sup; Seo, Seon Hee;Yang, Beom-Seok; Lee, Jae Yeol Archiv der Pharmazie (Weinheim,Germany) Volume 338 Issue 10 Pages 502-505 Journal 2005 5、Fluorine-18 labeling of 6,7-disubstituted anilinoquinazoline derivatives for positron emission tomography (PET) imaging of tyrosine kinase receptors: Synthesis of 18FIressa and related molecular probes. Seimbille, Yann; Phelps, Michael E.; Czernin, Johannes; Silverman, Daniel H. S. Journal of Labelled Compounds & Radiopharmaceuticals Volume 48 Issue 11 Pages 829-843 Journal 2005 6、 Kinetic study of a 2-hydroxypropyl - -cyclodextrin-based formulation of all -trans-retinoic acid in Sprague-Dawley rats after oral or intravenous administration. Lin HS,Chan SY,Low KS,et al. Journal of Pharmacological Sciences . 2000 7、 Design and in vivo testing of 17-beta estradial -HP beta CD sublingual tablets. Fridriksdottir H,Loftsson T,Gudmundsson JA,et al. Pharmazie . 1996 8、 Hydroxypropyl - -cyclodextrin derivatives: influence of average degree of substitution on complexing ability and surface activity. Muller BW,Brauns U. Journal of Pharmacological Sciences . 1986 9、 Cyclodextrins as co-enhancers in dermal and transdermal drug delivery. Loftsson T,Masson M,Sigurdsson HH,et al. Pharmazie . 1998 10、 Effect of 2hydroxypropyl - -cyclodextrin on percutaneous absorption   [更多]

任務(wù)要求： 請(qǐng)直接上傳附件，謝謝各位藥智的戰(zhàn)友們   [更多]

求購(gòu)替格瑞洛原料和制劑最新的標(biāo)準(zhǔn)一份   [更多]

    求購(gòu)葡萄糖酸鈣氯化鈉注射液過(guò)一評(píng)的質(zhì)量質(zhì)量信息   [更多]

  求購(gòu)醋酸鈉林格注射液過(guò)一評(píng)的質(zhì)量信息   [更多]

  求購(gòu)甘油果糖氯化鈉注射液過(guò)一評(píng)的質(zhì)量信息   [更多]

求購(gòu)復(fù)方倍他米松注射液標(biāo)準(zhǔn)07詳細(xì)版一份，要包含含量測(cè)試方法和條件的。   [更多]

請(qǐng)有資源的在這兒投稿   [更多]

文獻(xiàn)標(biāo)題: 1.Development and evaluation of chitosan based oral controlled matrix tablets of?losartan?potassium J Pharm Investig.?2012 Jul;2(3):157-61. doi: 10.4103/2230-973X.104399. 2.Response criteria of tolvaptan for the treatment of hepatic edema J Gastroenterol. 2017 Jun 29. 3.Hepatol Res.?2017 Oct 6. doi: 10.1111/hepr.12988. [Epub ahead of print] Increased?serum?C-reactive?protein?and?decreased?urinary?aquaporin?2?levels?are?predictive?of the?efficacy?of?tolvaptan?in?patients?with?liver?cirrhosis. 4.Highly linear pH gradients for analyzing monoclonal antibody charge heterogeneity in the alkaline range. 5.An evaluation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles 6.Anatol J Cardiol.?2017 Sep;18(3):213-214. doi: 10.14744/AnatolJCardiol.2017.8033. Tolvaptan?in the very elderly with acute decompensated heart failure- a therapeutic option worth of consideration. 7.紫外-可見(jiàn)分光光度法測(cè)定依達(dá)拉奉注射液中的亞硫酸氫鈉含量 8.Anatol J Cardiol. 2017 Sep;18(3):213-214. doi: 10.14744/AnatolJCardiol.2017.8033. Tolvaptan in the very elderly with acute decompensated heart failure- a therapeutic option worth of consideration. 備注: 將符合要求的文獻(xiàn)PDF格式打包上傳   [更多]

求購(gòu)熊去氧膽酸、?；切苋パ跄懰崮z囊注冊(cè)標(biāo)準(zhǔn)；都需要最新的標(biāo)準(zhǔn)   [更多]